rolapitant

Ligand id: 5749

Name: rolapitant

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 50.36
Molecular weight 500.19
XLogP 7.55
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Rolapitant is approved by the US FDA to treat chemotherapy-induced nausea and vomiting in combination with other antiemetic agents.
Mechanism Of Action and Pharmacodynamic Effects
Activation of NK-1 receptors plays a central role in nausea and vomiting induced by certain cancer chemotherapies. Rolapitant antagonises this receptor activation and so reduces symptoms.